AbbVie research-driven biopharmaceutical company.

Do you see patients with Myeloproliferative Neoplasms or Chronic Myelomonocytic Leukemia.

Learn about our research studies of an investigational agent targeting myelofibrosis and related diseases.

transforming lives Myelofibrosis Research
transforming lives Myelofibrosis Research

Our Studies

Patients who are diagnosed with myelofibrosis will experience constitutional symptoms, splenomegaly, an increased risk of transformation to acute myeloid leukemia (AML), and a shortened life expectancy. As an acquired clonal Philadelphia chromosome negative myeloproliferative neoplasm (MPN), myelofibrosis can present in a number of ways. Patients may be diagnosed with primary myelofibrosis or secondary myelofibrosis following progression of polycythemia vera (PV) to post-PV myelofibrosis, or essential thrombocythemia (ET) to post-ET myelofibrosis. Other than hematopoietic stem cell transplantation (HSCT), current therapies are unable to control all of the clinical manifestations of myelofibrosis. Our research is focusing on potential new treatment options, including combination strategies with ruxolitinib as the backbone treatment.

We are conducting several research studies to evaluate an investigational agent called navitoclax in patients with myelofibrosis and related diseases (polycythemia vera (PV), essential thrombocythemia (ET) and chronic myelomonocytic leukemia). The primary objective of this program is to evaluate the effect of navitoclax (in most cases, in combination with ruxolitinib) on reducing spleen volume in patients with myelofibrosis. We are also conducting a research study evaluating navitoclax monotherapy in patients across MPN disease types (including myelofibrosis, PV, and ET) and CMML. Patients in all of these studies may continue on the study treatment as long as they are receiving benefit. We need help from the local medical community to help us identify qualified study participants around the world.

Navitoclax is under clinical development and is not approved by regulatory health authorities. Safety and efficacy are under evaluation.

Transform 1- Myelofibrosis Research Studies
EXPLORE STUDY
EXPLORE STUDY
Transform Myelofibrosis Research Studies
EXPLORE STUDY
EXPLORE STUDY
EXPLORE STUDY
EXPLORE STUDY
AbbVie Myelofibrosis Research Studies

Enrollment has been closed

In the double-blind placebo-controlled Phase 3 TRANSFORM-1 study, the investigational medication (navitoclax) in combination with ruxolitinib will be compared to ruxolitinib with matching placebo, to evaluate its effect on splenomegaly, bone marrow fibrosis, anemia responses and quality of life.

Navitoclax, an investigational agent, is under clinical development and is not approved by regulatory health authorities. Safety and efficacy are under evaluation.

ClinicalTrials.gov Identifier: NCT04472598
EudraCT Number: 2020-000097-15

Myelofibrosis Research Study by AbbVie

In the randomized open-label Phase 3 TRANSFORM-2 study, the investigational medication (navitoclax) in combination with ruxolitinib is compared to best available therapy to evaluate its effect on splenomegaly, bone marrow fibrosis, anemia responses and quality of life in relapsed/refractory myelofibrosis patients.

  • Are 18 years of age or older
  • Have been diagnosed with primary myelofibrosis, post-polycythemia vera myelofibrosis, or post-essential thrombocythemia myelofibrosis, characterized by bone marrow fibrosis grades 2 or 3.
  • Currently have Intermediate-2 or High-Risk myelofibrosis
  • Have received prior treatment with a JAK-2 inhibitor therapy, ruxolitinib
        • Treatment with ruxolitinib for ≥ 24 weeks that was stopped due to lack of spleen response (refractory), or loss of spleen response or symptom control after a previous response (relapsed), or was continued despite relapsed/refractory status.
        • Treatment with ruxolitinib for < 24 weeks with documented disease progression
        • Prior or current treatment with ruxolitinib of at least 10 mg BID for ≥ 28 days with intolerance defined as new RBC transfusion requirement (at least 2 units/month for 2 months) while receiving a total daily ruxolitinib dose of ≥ 30 mg but unable to reduce dose further due to lack of efficacy.
Note: Subject must not require a ruxolitinib dose less than 10 mg BID (20 mg daily) due to prior history of ruxolitinibrelated ≥ Grade 3 toxicity
  • Have splenomegaly of at least 5 cm or spleen volume  ≥ 450 cm3
  • Have at least 2 symptoms each with an average score ≥ 3 or an average total score of ≥ 12, as measured by the MFSAF v4.0 prior to randomization. Subject must complete the MFSAF v4.0 on at least 4 out of the 7 days immediately prior to the date of randomization and must agree to collect MFSAF data daily by ePRO device during the study collection window.

Navitoclax, an investigational agent, is under clinical development and is not approved by regulatory health authorities. Safety and efficacy are under evaluation.

ClinicalTrials.gov Identifier: NCT04468984
EudraCT Number: 2020-000557-27

ENVELOP is a multi-part clinical research study for adults with MPN and Myelofibrosis (MF), enrolling in various global regions. This information will be focusing on Part 5 of the study.

Part 5 is for patients with MF who are requiring treatment and either have no prior treatment with a JAK2 inhibitor or have received ruxolitinib (prior or current) to evaluate the impact of navitoclax on the pharmacokinetics (PK) of ruxolitinib. After completing PK assessments, patients may continue to receive navitoclax and ruxolitinib in the study as long as they are receiving benefit and tolerating the combination.

Eligibility Criteria (Part 5)

  • Are 18 years of age or older
  • Have a documented diagnosis of primary MF as defined by the WHO classification, post-PV MF, or post-ET MF.
  • Classified as intermediate-2 or high-risk MF, as defined by the Dynamic International Prognostic Scoring System (DIPSS).
  • Requiring treatment for MF and must either have no prior treatment with a JAK2 inhibitor or have received treatment with ruxolitinib (current or prior treatment with ruxolitinib as noted in the protocol)
  • Have an ECOG performance status <=2.
  • Have adequate bone marrow, kidney, liver and hematology blood values as detailed in the protocol
Navitoclax, an investigational agent, is under clinical development and is not approved by regulatory health authorities. Safety and efficacy are under evaluation.

ClinicalTrials.gov Identifier: NCT04041050
EudraCT Number: 2020-000557-27

This website uses cookies to ensure you get the best experience on our website. View Privacy Policy Here.

Do Not Agree
AGREE